Viehbacher, "Biogen") announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI®" has been launched in South Korea. LEQEMBI received the Ministry ...

Lecanemab, marketed as Leqembi, is the first drug targeting the root cause of Alzheimer’s disease to be approved by the ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the ...

November is National Alzheimer’s Awareness Month.The Alliance for Aging Research is using this month to raise awareness about ...

The European Union's drugs regulator has recommended approval for Eisai and Biogen's Alzheimer's drug Leqembi. This marks a ...

first session of receive the newly FDA approved Alzheimer's treatment Leqembi while Williford's wife Cynthia Byron-Williford, 59, right, watches at Abington Neurological Associates in Abington ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Viehbacher, "Biogen") announced today that the humanized anti-soluble aggregated amyloid-beta (Aß) monoclonal antibody "LEQEMBI®" has been launched in South Korea. LEQEMBI received the ...

STOCKHOLM, Nov. 27, 2024 /PRNewswire/ - BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi ® (generic name: lecanemab) has been launched in South Korea.